LON:FEVR

LON:FEVR - Fevertree Drinks PLC

OPPORTUNISTIC BUYREDUCE ZONEConsumer Defensive - Beverages - Non-AlcoholicAnalysis generated 2026-10-28Market data as of 2026-11-13Market data 2 days old973.50p

Conviction

out of 100

Executive Summary

Fevertree Drinks PLC (LON:FEVR) designs and sells premium mixers, including tonic water, ginger beer, ginger ale and soda water, under the Fever-Tree brand, with production outsourced to third-party manufacturers and sales distributed through On-Trade, Off-Trade and international channels. It holds a leading position in the premium mixer category, particularly in the United Kingdom.

The investment case requires US expansion through the Molson Coors strategic licensing agreement to improve distribution and sales while the company addresses weakness in the UK On-Trade channel and input-cost volatility; the US partnership is the key near-term catalyst, although its rollout timing and financial contribution were not confirmed in the supplied research. The primary risk is that elevated valuation and persistent weakness in higher-margin UK On-Trade volumes leave little tolerance for disappointing execution.

OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would change if the Molson Coors agreement failed to generate measurable US distribution gains or if UK On-Trade weakness, private-label competition or input-cost inflation materially weakened earnings and cash generation.

Trim / take some off. Current price 973.50p is 2.8% above the trim line of 947.00p. Existing holders should reduce; new money should wait.

REDUCE ZONEOPPORTUNISTIC BUY · 59/100Now 973.50p · buy ≤ 822.33p · trim ≥ 947.00p

Thesis break: The thesis would be invalidated if the Molson Coors agreement is terminated or fails to produce measurable US distribution and sell-through, or if UK On-Trade revenue declines materially while group revenue growth falls below 2% and operating margin contracts.

Business Model

Fevertree earns revenue by selling branded premium mixers through three principal routes to market: On-Trade, comprising bars, restaurants, hotels and clubs; Off-Trade, comprising supermarkets, convenience stores and other food retailers; and international markets, including the United States. The company focuses on brand, formulation, marketing and route-to-market while using third-party manufacturers and distribution partners, limiting the need for direct capital-intensive production.

The strategic importance of On-Trade is greater than its revenue contribution alone suggests because the channel typically carries higher unit economics than supermarket sales. A decline in UK On-Trade demand therefore carries a disproportionate effect on profitability, particularly if the company must respond through discounting or increased trade investment. Off-Trade provides scale and visibility but is more exposed to private-label competition and retailer negotiating pressure.

Fevertree's principal competitive advantages are brand recognition, category leadership, differentiated premium positioning and established distributor relationships. The Molson Coors agreement adds a potential route into US distribution, but the supplied research does not confirm the commercial terms, minimum volumes, ownership of retail relationships or expected revenue contribution, so the scale of the opportunity remains unquantified.

Financial Snapshot

Price

973.50p

Market Cap

1.0bn

P/E Ratio

43.0x

52w High

973.00p

52w Low

711.00p

Distance from 52wH

0.1%

Avg Volume

560302

Currency

GBX

Recent Catalysts

[2026-04-14] - Fevertree Drinks PLC announced that it had purchased 127,130 ordinary shares between 7 April and 10 April 2026 through Investec Bank plc under the authority granted at the 2025 Annual General Meeting. The repurchased shares were intended to be cancelled, with reported volume-weighted average prices ranging from 769.0583p to 817.0306p. Source: Fevertree Drinks PLC regulatory announcement via Investegate.

[2026-03-26] - Jefferies Financial Group reaffirmed a Buy rating on Fevertree Drinks following the company's quarterly earnings release, providing public analyst support for the shares. The supplied research does not specify the accompanying target price. Source: Markets Daily.

[2026-03-24] - Fevertree Drinks released quarterly earnings data, providing investors with an update on trading performance, financial results and the operating backdrop. The supplied research does not include the full financial detail, so no specific revenue, margin or profit outcome is inferred here. Source: MarketBeat.

[2026-04-27 to 2026-05-01] - Fevertree Drinks repurchased ordinary shares during this period and subsequently announced the cancellation of 15,588 shares, reducing the share count after the latest buyback. The supplied research does not provide the aggregate purchase consideration for this tranche. Source: Fevertree Drinks PLC company announcement reported by TipRanks.

Thesis Evaluation

Bull Case (25% weight)

The Molson Coors licensing agreement delivers effective US distribution, broadens retail availability and supports sustained premium mixer growth without requiring Fevertree to build a disproportionate owned sales infrastructure. Group revenue growth accelerates and operating margins stabilise or improve as higher-margin US and On-Trade volumes offset input-cost pressure, supporting a price target of 1050p over 12 months.

Base Case (50% weight)

The Molson Coors agreement adds distribution and improves Fevertree's US presence, but the contribution develops more gradually and is partly offset by persistent UK On-Trade weakness and competitive pressure in Off-Trade. Revenue growth remains modest while earnings are broadly stable, producing a 12-month price target of 947p.

Bear Case (25% weight)

US expansion fails to generate meaningful sell-through, while UK On-Trade volumes and premium pricing remain under pressure from private labels and weak hospitality demand. Higher input costs prevent a margin recovery, causing earnings growth to stall or contract and the valuation to de-rate, with a price target of 760p over 12 months.

Weighted conviction:Bull (25%) x 100 + Base (50%) x 62 + Bear (25%) x 10 = 59/100. OPPORTUNISTIC BUY.

Key Risks

UK On-Trade contraction: Persistent weakness in the higher-margin UK On-Trade channel could erode revenue and profit disproportionately because of its superior unit economics. Estimated probability: 45%. Impact: moderate.
US partnership execution: The Molson Coors strategic licensing agreement may deliver slower distribution, weaker consumer conversion or less benefit than investors expect because the commercial terms and rollout milestones are not confirmed in the supplied research. Estimated probability: 35%. Impact: severe.
Input-cost inflation: Higher costs for ingredients, packaging and logistics could compress gross and operating margins if Fevertree cannot pass the increase through to consumers or retailers. Estimated probability: 40%. Impact: moderate.
Private-label competition: Competition from cheaper private-label mixers could limit price increases and force greater promotional spending, especially in the UK Off-Trade channel. Estimated probability: 40%. Impact: moderate.
Valuation compression: The reported current price of 921p is 5.3% below the 52-week high of 973p, leaving the shares exposed to a de-rating if earnings growth remains modest relative to the current earnings multiple. Estimated probability: 35%. Impact: moderate.
Manufacturing and supply-chain dependence: Reliance on third-party manufacturers and distributors exposes the business to production disruption, logistics constraints and weaker control over product availability and costs. Estimated probability: 25%. Impact: moderate.

Who Should Own It / Avoid It

Ideal for: Growth-oriented investors who accept a medium-risk holding, can tolerate material share-price volatility and are prepared to hold the position for at least 12 months while assessing US distribution progress, margin delivery and the extent of UK On-Trade stabilisation.

Avoid if: You require a high-income, low-volatility defensive profile, cannot tolerate an earnings-multiple contraction or prefer businesses with limited dependence on discretionary hospitality spending, outsourced manufacturing and concentrated premium-mixer brand economics.

Recommendation

OPPORTUNISTIC BUY - 59/100 - Fevertree combines category leadership, an identifiable US distribution catalyst and improving capital returns through share repurchases, but the shares already discount a meaningful portion of the growth case. The rating would upgrade if the Molson Coors agreement produces measurable US sell-through, evidence of better revenue growth and sustained margin recovery alongside stabilisation in UK On-Trade. It would degrade if US expansion disappoints, UK On-Trade weakness persists or input costs and private-label competition prevent earnings growth. At the current price of 973.50p the shares trade at or above our base-case target of 947.00p: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above 822.33p.

The probability-weighted value across our three scenarios is 926.00p, 5% below the current price of 973.50p - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.

BUY

below 822.33p - below this level the upside to the base-case target (947.00p) is at least 2x the downside to the bear case (760.00p), the minimum risk/reward we require before committing new capital.

HOLD

between 822.33p and 947.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.

REDUCE

above 947.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.

SELL

if the thesis would be invalidated if the Molson Coors agreement is terminated or fails to produce measurable US distribution and sell-through, or if UK On-Trade revenue declines materially while group revenue growth falls below 2% and operating margin contracts, regardless of price - the bear target of 760.00p is the backstop, not an arbitrary percentage stop.

Conviction Trend

Latest conviction: 59/100. Trend versus prior report: Initiation.

CONVICTION BUY (80+)BUY (65 - 79)OPP BUY (50 - 64)SPEC BUY (30 - 49)AVOID (0 - 29)

Report date	Conviction
2026-10-28	59

See the trade-card view →

Sources

Market data: DYOR HQ proprietary market data workflow.

Public sentiment and news flow: Public company announcements, regulatory filings, quarterly earnings coverage and analyst commentary were reviewed, including material on the Molson Coors partnership, quarterly results, the reaffirmed Jefferies Buy rating and share buyback activity.

Primary source types: Regulatory announcements, company investor relations materials, quarterly earnings information, company disclosures and third-party financial news and analyst commentary.

Key sources

Analysis generated 2026-10-28. Market data as of 2026-11-13.